Efficacy of Empagliflozin Combined with Liraglutide in the Treatment of Obese Type 2 Diabetes Mellitus
薛刚霞 1王静 2卫丽霞2
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 运城护理职业学院内科教研室,山西运城 044000
2. 运城市盐湖区人民医院内分泌科,山西运城 044000
折叠
摘要
目的 研究恩格列净(Empagliflozin,EMPA)联合利拉鲁肽(Liraglutide,LIRA)治疗肥胖2型糖尿病(Type 2 Diabetes Mellitus,T2DM)的疗效.方法 选取2022年5月—2023年8月运城市盐湖区人民医院收治的72例肥胖T2DM患者为研究对象,根据随机数表法分为观察组(n=36)与对照组(n=36),两组均接受饮食和运动干预,观察组行EMPA联合LIRA治疗,对照组单用EMPA治疗;比较两组治疗前与治疗6个月后体质指数(Body Mass Index,BMI)、血糖[糖化血红蛋白(Glycted Hemoglobin,HbA1c)、餐后2 h血糖(2-hour Postprandial Blood Glucose,2 hPG)、空腹血糖(Fasting Blood Glucose,FBG)]水平、胰岛功能[胰岛β细胞功能指数(Homeostasis Model Assessment-β,HOMA-β)、胰岛素抵抗指数(Homeostatic Model Assessment of Insulin Resistance,HOMA-IR)].结果 治疗前,两组BMI、血糖及胰岛功能比较,差异无统计学意义(P均>0.05);治疗后,两组BMI、血糖与HOMA-IR低于治疗前,HOMA-β高于治疗前,差异有统计学意义(P均<0.05);观察组HOMA-β高于对照组,BMI、HbA1c、2 hPG、FBG、HOMA-IR低于对照组,差异有统计学意义(P均<0.05).结论 EMPA联合LIRA治疗肥胖T2DM的疗效显著,可进一步改善患者的BMI、血糖水平与保护胰岛功能.
Abstract
Objective To investigate the efficacy of empagliflozin(EMPA)combined with liraglutide(LIRA)in the treatment of type 2 diabetes mellitus(T2DM).Methods Selected 72 obese T2DM patients admitted to Yanhu District People's Hospital of Yuncheng City from May 2022 to August 2023 as the study objects,according to the random num-ber table method they were divided into observation group(n=36)and control group(n=36).Both groups received diet and exercise intervention,the observation group received EMPA combined with LIRA,and the control group received EMPA alone.Compared the body mass index(BMI),the levels of blood glucose[glycated hemoglobin(HbA1c),2-hour postprandial blood glucose(2 hBG),fasting blood glucose(FBG)],islet function[homeostasis model assessment-β(HOMA-β),homeostatic Model Assessment of Insulin Resistance(HOMA-IR)]of the two groups.Results Before treatment,there was no statistically significant difference in BMI,blood glucose and islet function between the two groups(all P>0.05).After treatment,BMI,blood glucose and HOMA-IR of two groups were lower than before treat-ment,and HOMA-β was higher than before treatment,and the differences were statistically significant(all P<0.05);HOMA-β of the observation group was higher than that of the control group,and BMI,HbA1c,2 hBG,FBG,and HOMA-IR of the observation group were lower than those of the control group,and the differences were statistically significant(all P<0.05).Conclusion EMPA combined with LIRA is effective in the treatment of obese T2DM,which can further improve BMI,blood glucose level and protect islet function.
关键词
恩格列净/利拉鲁肽/肥胖/2型糖尿病/胰岛功能
Key words
Empagliflozin/Liraglutide/Obesity/Type 2 diabetes/Islet function
维普
万方数据